All In Biotech

Drug Trial Radar · NCT04958239

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

151

Actual

Start

Oct 18, 2021

Primary completion

Apr 27, 2026

Study completion Feb 17, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of Part 1 of this study is to find the highest dose of a medicine called BI 765179 that people with solid tumors can tolerate when taken alone or together with a medicine called ezabenlimab. The goal of Part 2 is to find out whether BI 765179 in combination with a medicine called pembrolizumab helps people with advanced head and neck cancer. In Part 1, each participant is put into 1 of 2 groups. Participants get BI 765179 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. In Part 2, participants are also divided into 2 groups. 1 group gets a low dose of BI 765179 in combination with pembrolizumab and the other group gets a high dose of BI 765179 in combination with pembrolizumab. Participants receive the study treatment as infusions into a vein. BI 765179, ezabenlimab, and pembrolizumab are antibodies that may help the immune system fight cancer. In this study, BI 765179 is given to people for the first time. Participants can stay in the study up to 2 years if they benefit from treatment and can tolerate it. The doctors regularly check the participants' health and note any health problems that could have been caused by the study treatment.

Conditions

  • Neoplasms

Interventions

  • BI 765179Drug

    BI 765179

  • EzabenlimabDrug

    Ezabenlimab

  • PembrolizumabDrug

    Pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Maximum Tolerated Dose (MTD)Time frame: Up to Day 21 (end of Cycle 1)
  2. Phase 1a: Occurrence of Dose Limiting Toxicities (DLTs) in the MTD evaluation periodTime frame: Up to Day 21 (end of Cycle 1)
  3. Phase 1b: Objective response (OR)Time frame: Up to 2 years.

Locations

48 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • NEXT Oncology-San Antonio-65273

    San Antonio, Texas

  • Border Cancer Hospital

    Albury, New South Wales, Australia

  • Kinghorn Cancer Centre

    Darlinghurst, New South Wales, Australia

  • Townsville Hospital

    Douglas, Queensland, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • AZ Groeninge

    Kortrijk, Belgium

  • ICESP - Instituto do Cancer do Estado de Sao Paulo

    São Paulo, Brazil

  • Hospital Sírio Libanês-São Paulo-68088

    São Paulo, Brazil

  • Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência

    São Paulo, Brazil

  • The First Affiliated Hospital Of Bengbu Medical College

    Bengbu, China

  • Hunan Province Tumor Hospital

    Changsha, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Masaryk Memorial Cancer Institute

    Brno, Czechia

  • HOP Saint-André

    Bordeaux, France

  • CTR Georges-François Leclerc

    Dijon, France

  • INS Cancérologie Ouest Saint-Herblain

    Saint-Herblain, France

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Martin-Luther-Universität Halle-Wittenberg

    Halle, Germany

  • Klinikum Stuttgart

    Stuttgart, Germany

  • Shaare-Zedek Medical Center, Oncology Institute

    Jerusalem, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • Istituto Nazionale IRCCS Tumori Fondazione Pascale

    Naples, Italy

  • Aichi Cancer Center Hospital

    Aichi, Nagoya, Japan

  • National Cancer Center Hospital East

    Chiba, Kashiwa, Japan

  • Kanagawa Cancer Center

    Kanagawa, Yokohama, Japan

  • Kansai Medical University Hospital

    Osaka, Hirakata, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • Instituto Nacional de Cancerologia

    México, Mexico

  • Centro Oncologico Internacional

    Mexico City, Mexico

  • Hospital Universitario Dr Jose Eleuterio Gonzalez

    Monterrey, Mexico

  • Fundación Santos y de la Garza Evia, I.B.P

    Monterrey, Mexico

  • VU University Medical Center

    Amsterdam, Netherlands

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.